Skip to main content

Table 2 Dysgeusia experienced in each patient

From: Preliminary estimation of the prevalence of chemotherapy-induced dysgeusia in Japanese patients with cancer

Age

≤59

60–69

70–79

≥80

Total

Therapy

     

5-FU total

4/6 (66.7)

2/10 (20.0)

4/8 (50.0)

3/3 (100)

13/27 (48.1)

Oral analogs

2/3 (66.7)

2/7 (28.6)

4/6 (66.7)

2/2 (100)

10/18 (55.6)

5-FU

2/3 (66.7)

0/3 (0)

0/2 (0)

1/1 (100)

3/9 (33.3)

Pt

2/3 (66.7)

2/9 (22.2)

0/4 (0)

-

16/38 (42.1)

Tx

1/3 (33.3)

0/1 (0)

1/1 (100)

-

5/38 (13.2)

Others

0/3 (0)

1/6 (16.7)

0/1 (0)

-

1/10 (10.0)

Off

0/2 (0)

1/3 (33.3)

1/3 (33.3)

-

2/8 (25.0)

  1. The number of patients who experienced dysgeusia during therapy is indicated per total number undergoing chemotherapy. Numbers in parentheses indicate the percentage. Type of chemotherapy is indicated in the first column. Off off-chemotherapy.
Back to article page

BMC Palliative Care

ISSN: 1472-684X

Contact us